CAMYLOFIN HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H32N2O2.2ClH
Molecular Weight	393.391
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1

InChI

InChIKey=ZHRVNCCPAKIGRH-UHFFFAOYSA-N

InChI=1S/C19H32N2O2.2ClH/c1-5-21(6-2)14-13-20-18(17-10-8-7-9-11-17)19(22)23-15-12-16(3)4;;/h7-11,16,18,20H,5-6,12-15H2,1-4H3;2*1H

HIDE SMILES / InChI

Description
Sources: http://www.drugsupdate.com/generic/view/753/Camylofin
Curator's Comment: Description was created based on several sources, including http://www.ijrcog.org/index.php/ijrcog/article/view/1419

Camylofin is an antimuscarinic. This medication is used as antispasmodic in biliary colic, renal and ureteric colic, dysmenorrhoea, peptic ulcer and chronic enterocolitis. It is used to treat stomach ache in infants and children. Camylofin should be the first choice and may be preferred over other drugs for cervical dilatation and acceleration of active phase of labor.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D07076	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Labor complications 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22895986 https://www.ncbi.nlm.nih.gov/pubmed/23737030 https://www.ncbi.nlm.nih.gov/pubmed/24179892 http://www.ijrcog.org/index.php/ijrcog/article/view/1419	Primary		Approved 8429	ANAFORTAN Approved Use Camylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity.
Spasm 18 Sources: http://www.druginfosys.com/drug.aspx?drugcode=833&type=1 http://www.medclik.com/General/pages/Drugmanual/BrandSearch/ANAFORTAN.asp	Primary		Approved 8429	ANAFORTAN Approved Use Camylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity.

PubMed

Title	Date	PubMed
[Pharmacology of Avacan].	1951 Apr 6	14831430
A study of metabolism of isoamyl alpha-[N-(beta-diethylamino-ethyl)]-aminophenylacetate (avacan).	1956 Mar	13331655
Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection.	2007 Jan-Feb	17373440
Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis.	2010 Sep	20088681
Antispasmodics for labour.	2012 Aug 15	22895986

Patents

Sample Use Guides

In Vivo Use Guide

0.285 to 0.857 mg/kg to be taken every 8 hrs.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

CAMYLOFIN HYDROCHLORIDE

Common Name

English

CAMYLOFINE DIHYDROCHLORIDE [MI]

Common Name

English

ISOPENTYL 2-(2-DIETHYLAMINOETHYLAMINO)-2-PHENYLACETATE DIHYDROCHLORIDE

Systematic Name

English

CAMYLOFIN HCL

Common Name

English

ACAMYLOPHENINE HYDROCHLORIDE [JAN]

Common Name

English

Camylofin hydrochloride [WHO-DD]

Common Name

English

CAMYLOFIN HYDROCHLORIDE [MART.]

Common Name

English

ACAMYLOPHENINE HYDROCHLORIDE

Common Name

English

NSC-759249

Code

English

CAMYLOPHENINE DIHYDROCHLORIDE

Common Name

English

CAMYLOFINE HYDROCHLORIDE

Common Name

English

Code System Code Type Description

MESH

C004644